Chimerix (CMRX) Stock Price, News & Analysis

-0.02 (-2.16%)
(As of 04/24/2024 ET)
Today's Range
50-Day Range
52-Week Range
88,198 shs
Average Volume
395,092 shs
Market Capitalization
$80.82 million
P/E Ratio
Dividend Yield
Price Target

Chimerix MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
783.0% Upside
$8.00 Price Target
Short Interest
1.56% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.30mentions of Chimerix in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$6,598 Sold Last Quarter
Proj. Earnings Growth
From ($0.77) to ($0.95) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.12 out of 5 stars

Medical Sector

154th out of 907 stocks

Pharmaceutical Preparations Industry

57th out of 421 stocks

CMRX stock logo

About Chimerix Stock (NASDAQ:CMRX)

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

CMRX Stock Price History

CMRX Stock News Headlines

Just Released: Insider's Secret to Trading Options
This Surprisingly Simple Formula Can Double Your Money Collecting Consistent Profits From The Stock Market Is More Accessible Than You Think A small group of individuals are using a legitimate yet rarely discussed strategy to generate income from the stock market. They're NOT day traders. And they're NOT Wall Street suits either. I'm talking about normal "working stiffs" and retirees generating steady income from a source that 99% of investors completely overlook. This overlooked income source can be yours today.
CMRX Apr 2024 2.000 call
CMRX Apr 2024 1.000 put
The system that called 2023’s top 7 stocks is at it again…
Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.
Preview: Chimerix's Earnings
Chimerix Appoints Lisa Decker to Board of Directors
Positive Signs As Multiple Insiders Buy Chimerix Stock
See More Headlines
Receive CMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chimerix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
3 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$2.17 per share


Free Float
Market Cap
$80.82 million

Social Links

10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Michael T. Andriole M.B.A. (Age 51)
    CEO, President & Director
    Comp: $592.95k
  • Dr. Allen S. Melemed M.B.A. (Age 60)
    M.D., Chief Medical Officer
    Comp: $605.29k
  • Ms. Michelle LaSpaluto (Age 49)
    Chief Financial Officer
  • Mr. Thomas J. Riga (Age 48)
    Chief Operating & Commercial Officer
  • Mr. David Jakeman CPA (Age 46)
    VP of Accounting & Finance
  • Dr. Joshua E. Allen Ph.D.
    Chief Technology Officer
  • Dr. Michael A. Alrutz J.D. (Age 54)
    Ph.D., Senior VP, General Counsel & Corporate Secretary
    Comp: $619.5k
  • Dr. Roy W. Ware MBA
    Ph.D., Chief Manufacturing Technology Officer
  • Dr. Pablo Lee M.D.
    Head of Medical Affairs

CMRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Chimerix stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CMRX shares.
View CMRX analyst ratings
or view top-rated stocks.

What is Chimerix's stock price target for 2024?

3 Wall Street analysts have issued 1 year price targets for Chimerix's stock. Their CMRX share price targets range from $6.00 to $11.00. On average, they expect the company's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 783.0% from the stock's current price.
View analysts price targets for CMRX
or view top-rated stocks among Wall Street analysts.

How have CMRX shares performed in 2024?

Chimerix's stock was trading at $0.9625 at the beginning of 2024. Since then, CMRX shares have decreased by 5.9% and is now trading at $0.9060.
View the best growth stocks for 2024 here

When is Chimerix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CMRX earnings forecast

How were Chimerix's earnings last quarter?

Chimerix, Inc. (NASDAQ:CMRX) issued its quarterly earnings data on Thursday, February, 29th. The biopharmaceutical company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.03. Chimerix had a negative net margin of 25,337.96% and a negative trailing twelve-month return on equity of 37.93%.

What other stocks do shareholders of Chimerix own?
Who are Chimerix's major shareholders?

Chimerix's stock is owned by a number of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.51%). Insiders that own company stock include David Jakeman, Fred A Middleton, Martha J Demski, Michael T Andriole, Michelle Laspaluto and Robert J Meyer.
View institutional ownership trends

How do I buy shares of Chimerix?

Shares of CMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CMRX) was last updated on 4/25/2024 by Staff

From Our Partners